Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ...

Avidity Biosciences, Inc.’s RNA share price has surged by 6.34%, which has investors questioning if this is right time to ...

Genomics company, Integrated DNA Technologies, is rewriting the future of genomics, pioneering new innovations in a bold move ...

The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG. Click here to ...

AMX0114 is an antisense oligonucleotide made to prevent or slow the degeneration of axons, which is a key driver of ALS ...

Learn more about whether Alvotech or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Artivion, Inc. , a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2025 financial results will be released on Monday, May 5, 2025, after the ...

Multiplex real-time PCR-based diagnostic tests facilitate the simultaneous detection of multiple pathogens in a single assay, ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

This Review summarizes the current state of knowledge of DNA and RNA oligonucleotide hybridization kinetics, discusses new insights into the dynamics of hybridization and the duplex, and ...